ACHC

Rating neutralAI Memo

Acadia Healthcare

As of 2026-07-31/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

high

Horizon

—

Key catalyst

Q2 results and upgraded 2026 cash-flow guidance • 2026-07-28

Base target: $33 / p=50% prob

Biggest risk

The quarter itself was mixed: revenue was approximately flat, adjusted EBITDA fell 26%, adjusted EPS fell 54%, Specialty Treatment revenue declined 8.4%, and PLGL reserves remained a material drag. No verified post-print analyst estimate or target revisions were available.

Invalidation

Break below $22 or thesis failure.

What would change my mind?

The positive revision is mainly forward-looking: 2026 adjusted EBITDA, adjusted EPS, operating cash flow, and capex guidance improved, while capacity expansion and occupancy ramps could support second-half recovery [#SEC-8K-2026-07-28].

Research note

Recommendation

neutral

Confidence

high

As of

2026-07-31

Base target

$33

p=50%

Bull target

$37

p=25%

Bear target

$22

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Reserve, reimbursement, and specialty-facility pressure
Occupancy ramp and newly added capacity
The positive revision is mainly forward-looking: 2026 adjusted EBITDA, adjusted EPS, operating cash flow, and capex guidance improved, while capacity expansion and occupancy ramps could support second-half recovery [#SEC-8K-2026-07-28].

BearKey bullets

Medicaid financing changes, payer mix, and reimbursement pressure could weigh on admissions, pricing, and specialty-facility performance [#SEC-8K-2026-07-28].
Net leverage was 4.1x adjusted EBITDA at June 30, 2026, limiting flexibility if operating performance weakens [#SEC-8K-2026-07-28].
PLGL reserve development, litigation, and regulatory costs could continue to pressure EBITDA and cash flow [#SEC-8K-2026-07-28].

WatchKey bullets

Q2 results and upgraded 2026 cash-flow guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $33 (p=50%)

Target spread vs base: +12% / -33%

Scenario probabilities

Bull Target: $37 (p=25%)Base Target: $33 (p=50%)Bear Target: $22 (p=25%)

Commentary

News tone is mixed: the company raised several full-year guidance ranges, but the reported earnings profile was weaker year over year. The $28.14 July 30 anchor indicates weak post-release price action, though the packet does not provide a clean event-window return or attribution. Post-print analyst revisions and options/social coverage are unavailable, so confidence remains moderate.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Reserve, reimbursement, and specialty-facility pressure
Occupancy ramp and newly added capacity

Scenarios

Bull Target (Scenario probability)

$37 / p=25% prob

Base Target (Scenario probability)

$33 / p=50% prob

Bear Target (Scenario probability)

$22 / p=25% prob

Analysis 2026-07-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-28
Q2 results and upgraded 2026 cash-flow guidance
Q2 revenue was $865.8 million and adjusted EBITDA was $149.2 million, while management raised the 2026 adjusted EBITDA, adjusted EPS, and operating-cash-flow ranges and lowered planned capex. The release did not provide a verified consensus comparison, so the surprise signal remains uncertain [#SEC-8K-2026-07-28].
Prob 100.00% • Move 0.00% • Priced-in 100.00%

Short-term Catalysts

Next few weeks

Reserve, reimbursement, and specialty-facility pressure
2026-12-31
Adjusted EBITDA declined year over year, including a $28.6 million PLGL reserve adjustment; Specialty Treatment revenue fell 8.4%, while management continues to flag payer, regulatory, litigation, and reserve uncertainty [#SEC-8K-2026-07-28].
Prob 70% • Move -10% • Priced-in 60%

Long-term Catalysts

Months to a year

Occupancy ramp and newly added capacity
2026-12-31
Acadia added 240 licensed beds in Q2, opened two joint-venture facilities, and said it expects further progress in the second half from occupancy ramps at recently opened facilities [#SEC-8K-2026-07-28].
Prob 65% • Move 12% • Priced-in 45%

Risks

Medicaid financing changes, payer mix, and reimbursement pressure could weigh on admissions, pricing, and specialty-facility performance [#SEC-8K-2026-07-28].
Net leverage was 4.1x adjusted EBITDA at June 30, 2026, limiting flexibility if operating performance weakens [#SEC-8K-2026-07-28].
PLGL reserve development, litigation, and regulatory costs could continue to pressure EBITDA and cash flow [#SEC-8K-2026-07-28].
The company’s guidance excludes future acquisitions, transactions, legal costs, and non-recurring legal settlements, leaving downside visibility incomplete [#SEC-8K-2026-07-28].

Peers

Symbol	Summary
UHS	Closest large public behavioral-health operating peer; useful for comparing inpatient demand, reimbursement, and margin normalization.
LFST	Partial outpatient behavioral-health peer; useful for checking broader mental-health demand and reimbursement trends, but less comparable to ACHC's inpatient-heavy model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

Loading AI feed…

Symbol

Summary

UHS

Closest large public behavioral-health operating peer; useful for comparing inpatient demand, reimbursement, and margin normalization.

LFST

Partial outpatient behavioral-health peer; useful for checking broader mental-health demand and reimbursement trends, but less comparable to ACHC's inpatient-heavy model.